Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study
Neuro-Oncology Advances · 06.01.2025 · 7 (1)
DOI: 10.1093/noajnl/vdaf088 ↗Kurz gefasst
Fachartikel in der Zeitschrift Neuro-Oncology Advances, online erschienen am 28.04.2025. Verfasst von Keng Lam und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 32 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute, National Institutes of Health.
Abstract (Originalsprache)
Background
Several molecular alterations have been identified to provide prognosis for patients with isocitrate dehydrogenase (IDH)-mutant astrocytoma. However, contemporary baseline survival data with respect to their molecular alterations are lacking. The prognostic value of histologic grading remains controversial.
Methods
This was a retrospective multi-site study of adult IDH-mutant diffuse astrocytoma patients. Overall survival (OS) was estimated using the Kaplan-Meier method. Associations between OS and measures of interest were evaluated using Cox proportional hazards regression models.
Results
We identified 241 eligible patients. The most frequent mutations were IDH1 (98%), TP53 (91%), ATRX (70%), ARID1A (8%), BRCA2 (6%), TSC2 (6%), CDKN2A (6%), and CREBBP (6%). IDH2 mutations were identified in 2%. By univariate analysis, age > 40 (hazard ratio [HR], 2.03; 95% CI, 1.20-3.45; p = .009) was associated with worse OS. Wildtype BRCA2 compared with mutated BRCA2 (HR, 0.42; 95% CI, 0.20-0.90; p = .024) and Central Nervous System World Health Organization (CNS WHO) grade 2 astrocytoma compared with grade 3 disease (HR, 0.40; 95% CI, 0.21-0.78; p = .007) were associated with better OS. In multivariable analysis, age > 40 (HR, 2.06; 95% CI, 1.18-3.59; p = .011) was associated with worse OS and CNS WHO grade 2 (HR, 0.42; 95% CI, 0.21-0.83; p = .012) remained associated with improved OS. We identified an association between increased tumor mutation burden (TMB) and worse OS.
Conclusions
Age and CNS WHO grade remain essentials for risk stratification among IDH-mutant astrocytoma patients. Further studies are warranted to determine the prognostic implications of BRCA2 mutations and TMB.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neuro-Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
- Department of Pathology, University of Southern California.
- Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Texas, USA.
- Department of Neurosurgery, The University of Texas Health Science Center at Houston, Houston, Texas, USA.
- Department of Neuroradiology, The University of Texas MD Anderson Cancer, Houston, USA.
- Radiology and Biomedical Imaging, Yale University, New Haven, USA.
ORCID-Profile: Keng Lam, Antonio Dono, Yoshua Esquenazi, Chirag B Patel, Leomar Y Ballester
Förderung
- NCI NIH HHS
- National Cancer Institute
- National Institutes of Health
Zitieren
APA
Lam, K., Ozkizilkaya, H. I., Milton, D. R., Dono, A., Liu, Y., Kundu, S., Kumar, V. A., Johnson, J. M., Esquenazi, Y., Patel, C. B., & Ballester, L. Y. (2025). Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study. Neuro-Oncology Advances, 7(1). https://doi.org/10.1093/noajnl/vdaf088
Vancouver
Lam K, Ozkizilkaya HI, Milton DR, Dono A, Liu Y, Kundu S, et al. Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study. Neuro-Oncology Advances. 2025;7(1). doi:10.1093/noajnl/vdaf088
BibTeX
@article{Lam2025,
author = {Lam, Keng and Ozkizilkaya, Hanim I and Milton, Denái R and Dono, Antonio and Liu, Yajie and Kundu, Suprateek and Kumar, Vinodh A and Johnson, Jason M and Esquenazi, Yoshua and Patel, Chirag B and Ballester, Leomar Y},
title = {Molecular alterations in IDH -mutant astrocytoma: A multi-institutional retrospective study},
journal = {Neuro-Oncology Advances},
year = {2025},
volume = {7},
number = {1},
doi = {10.1093/noajnl/vdaf088}
}
EUVIMED